Lantheus Holdings



Credit Suisse 30th Annual Healthcare Conference Presentation

November 11, 2021

FIND > FIGHT > FOLLOW™

Safe Harbor Statements

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “anticipate,” “believe,” “confident,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will,” “would” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include : (i) the impact of the global COVID-19 pandemic on our business, financial conditions and prospects, and on the timing and enrollment of our clinical trials; (ii) continued market expansion and penetration for our commercial products, particularly DEFINITY, in the face of segment competition and potential generic competition, including as a result of patent and regulatory exclusivity expirations; (iii) our ability to successfully launch PYLARIFY as a commercial product, including (A) our ability to obtain U.S. Food and Drug Administration (“FDA”) approval for additional PET manufacturing facilities (“PMFs”) that could manufacture PYLARIFY, (B) the ability of those PMFs to supply PYLARIFY to customers, and (C) our ability to sell PYLARIFY to customers; (iv) the global Molybdenum-99 supply; (v) our products manufactured at Jubilant HollisterStier and our modified formulation of DEFINITY (“DEFINITY RT”) to be commercially manufactured at Samsung Biologics, including our ability to renew, modify or replace those agreements as may be necessary; (vi) the continued integration of the Progenics products and product candidate portfolio into our business following the Progenics Acquisition; (vii) our ability to use in-house manufacturing capacity; (viii) our ability to successfully launch aPROMISE, otherwise known as PYLARIFY AI, as a commercial product; (ix) the potential reclassification by the FDA of certain of our products and product candidates from drugs to devices with the expense, complexity and potentially more limited competitive protection such reclassification could cause; (x) the efforts and timing for clinical development of our product candidates and new clinical applications for our products, in each case, that we or our strategic partners may develop, including 1095 and flurpiridaz F 18; (xi) our ability to develop highly contextualized assessments of disease burden using artificial intelligence (“AI”); and (xii) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

65 years of imaging innovation

Most used radiopharmaceutical imaging agent in the U.S.[1]

Nearly 50 years of Technetium Tc-99m generator manufacturing expertise

#1 ultrasound enhancing agent used in the U.S. for 20 years[2]

(1) Sestamibi was the most used radiopharmaceutical in the U.S. based on procedure volume, DRG 2019 Imaging Market Guide.
(2) DRG Echo Monthly Monitor.

Precision Diagnostics

Our leading diagnostic products assist healthcare professionals (HCPs) in Finding and Following diseases in non-oncologic conditions

Radiopharmaceutical Oncology

Diagnostics and therapeutics that aid HCPs in Finding, Fighting and Following cancer

Strategic Partnerships and Other

Strategic partnerships with a focus on enabling precision medicine with biomarkers, digital solutions and radiotherapeutic platforms

Lantheus, a Growth Company – Driven by a Diversified Portfolio

THREE PORTFOLIO CATEGORIES

1 PRECISION DIAGNOSTICS

- DEFINITY® (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION
- DEFINITY® RT (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION
- TechneLite® Technetium Tc 99m Generator
- Xenon Xe 133 Gas
- NEUROLITE® Kit for the Preparation of Technetium Tc 99m Bicisate for Injection
- Cardiolite® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection
- Thallium Thallous Chloride Tl 201 Injection
- Gallium Gallium Citrate Ga 67 Injection

2 RADIOPHARMACEUTICAL ONCOLOGY

- PYLARIFY® Piflufolastat F 18 Injection
- PYLARIFY AI™
- AZEDRA® iobenguane I 131 injection for intravenous use
- 1095*
- LMI 1195*

3 STRATEGIC PARTNERSHIPS & OTHER

Pharma Services: Biomarkers

- NTI-1309* NORIA
- NM-01* NANOMAB
- BAYER
- POINT BIOPHARMA
- reflexion REGENERON

Microbubble Partnerships

- CARTHERA Advanced Brain Therapy Through Innovation
- CEREVAST™
- INSIGHTEC®
- AHN

- aBSI AUTOMATED BONE SCAN INDEX
- RELISTOR® methylnaltrexone bromide
- BAUSCH Health
- piflufolastat F 18*
- CURIUM™ EU ONLY
- flurpiridaz*
- GE Healthcare
- 1404*
- ROTOP

* Product candidates

Highlighted Products

Lantheus Holdings

PRECISION DIAGNOSTICS

Microbubbles
DEFINITY brand

Lantheus Holdings

Significant U.S. Echocardiography Market Opportunity Remains for DEFINITY

20% (~6 million) are considered **suboptimal**[2]

80% market share among agents used in suboptimal echocardiograms[3]



Unenhanced



DEFINITY® [a]
VIAL FOR (Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

[a]Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension. 1. ©2020 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission 2. 20% of echocardiograms result in sub-optimal images. Source: Lindner JR. J. Am. Coll. Cardiol. 2017:1-9. 3. Lantheus estimate.

DEFINITY: A Trusted Choice for More Than 20 Years

#1 Ultrasound Enhancing Agent

DEFINITY®
VIAL FOR (Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

- Significant opportunity remains in the suboptimal echo market
- Q3 2021 DEFINITY demand exceeded pre-COVID-19 levels
- On-campus DEFINITY manufacturing facility: Supplemental New Drug Application (sNDA) filed with the FDA; review process expected to take ~4 months
  - Provides supply chain redundancy
  - Margin expansion opportunity

DEFINITY RT
(Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

- Room temperature formulation
- Provides customer flexibility
- DEFINITY RT commercially available in Q4 2021
- Well suited for inclusion in product kits utilizing microbubbles for therapeutic applications
- Orange Book listed patents through 2035

Currently under development for inclusion in kits utilizing microbubbles for therapeutic applications

PARTNERSHIPS WITH

CarThera Advanced Brain Therapy Through Innovation · INSIGHTEC® · CEREVAST™ · AHN

RADIOPHARMACEUTICAL ONCOLOGY

PYLARIFY®
Piflufolastat F 18 Injection



Lantheus Holdings

PYLARIFY®

Piflufolastat F 18 Injection

NOW APPROVED

PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.

Prostate Cancer PET Imaging: Large Addressable Market

Eligible Patients

~170K

Comprised of 130,000+ patients with suspected recurrence and 40,000+ patients with suspected metastasis[1]



Annual Potential

$600M+[2]



Not actual patients.

(1) Scher HI, Solo K, Valant J, Todd MB, Mehra M. 2015. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PloS one 10: e0139440.
(2) Addressable market based on: current management estimates, internal data and observed market price.

Prostate Cancer is the Second Most Common Cancer in American Men[1]

2021 **Prostate Cancer Estimates**

~248,530 new cases[1]

~34,130 deaths[1]



1:8 Diagnosed with prostate cancer during his lifetime[1]

Up to 50% Will experience a recurrence[2]

60%
65 or older
Average age of diagnosis is ~66

>3.1M Are living with prostate cancer today[1]

1:41 Will die of prostate cancer[1]

(1) American Cancer Society. *Cancer Facts & Figures 2021.* Atlanta: American Cancer Society; 2021.
(2) Ceci & Fanti. PSMA-PET/CT imaging in prostate cancer: why and when. Clinical and Translational Imaging volume 7, pages 377–379 (2019).

Prostate Cancer Patients May Receive Multiple Images During Their Disease Journey as Part of Diagnosis and Staging

Number of Potentially Eligible Patients within PYLARIFY Indications in 2021 = ~170K; Annual Potential $600M+[1]



(1) Scher HI, Solo K, Valant J, Todd MB, Mehra M. 2015. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PloS one 10: e0139440.; Addressable market based on: current management estimates, internal data and observed market price. Based on: CDC.gov, SEER Database, NCCN.org and Axiom Primary and Secondary Market Research and Analysis, validated by Bohm Epidemiology 2020.

Advantages of PYLARIFY

PET IMAGING[1,2]

PET/CT Scans:

- Have high detection rates of metastatic disease even in patients with low PSA
- Are not limited by the size of lymph nodes in detection of nodal disease
- Can visualize bone metastases when CT or bone scan cannot

PSMA TARGETING[3]

- PYLARIFY works by binding to PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells which enables the reader of the PET/CT scan to detect and locate the disease

F 18 RADIOISOTOPE[4]

- Attributes help deliver high quality, clear, detailed and reproducible images
- Cyclotron production offers high batch capacity
- 110-minute half-life allows for broad geographic distribution and clinical flexibility in administration

FUTURE TECHNOLOGY[5,6]

- PLYARIFY AI[7] – a proprietary, patent-protected artificial intelligence medical device software developed to assist with the reading and quantification of PYLARIFY scans
- Potential benefits of reader efficiency and reproducibility of PSMA PET/CT image assessments
- Regulatory Clearances:
  U.S. - 510(k)
  E.U. - CE mark

(1) Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019;11:1-14. doi:10.1177/1758835919876828.; (2) Rousseau E, Wilson D, Lacroix-Poisson F, et al. A prospective study on 18F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer. J Nucl Med. 2019;60(11):1587-1593. doi: 10.2967/jnumed.119.226381; (3) Ceci & Fanti. PSMA-PET/CT imaging in prostate cancer: why and when. Clinical and Translational Imaging volume 7, pages 377–379 (2019); (4) Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1-16; (5) Deep Learning-Enabled Comprehensive Detection and Quantification of 18FDCFPyL (PyL-PSMA) PET/CT. Brynolfsson J, Johnsson K, Sahlstedt H, Richter J, et al, OP-548, 1006: Cutting Edge Science Track – TROP Session: AI -Radiomics and Modelling, EANM 2020; (6) miPSMA Index: Comprehensive and Automated Quantification of 18F-DCFPyL (PyL-PSMA) PET/CT for Prostate Cancer Staging. Johnsson K, Sahlstedt H, Brynolfsson J, et al. J Nucl Med. 2020;61(1):1435. 7-Cleared under the name aPROMISE and will be launched under the name PYLARIFY AI

20 Activated PMFs as of November 1, 2021

Selectively flying doses into key markets in advance of PMF activation

AVAILABLE NOW

Arizona, Phoenix
California, Culver City
California, San Diego
Georgia, Atlanta
Illinois, Romeoville
Kentucky, Louisville
Louisiana, Covington
Massachusetts, Haverhill
Minnesota, Minneapolis
Missouri, Kansas City
New Jersey, Totowa
New Mexico, Albuquerque
North Carolina, Raleigh
Ohio, Oakwood Village
South Carolina, Columbia
Tennessee, Knoxville
Texas, Dallas
Texas, Houston
Virginia, Sterling
Washington, Seattle

PLANNED FUTURE SITES

California, Gilroy
Colorado, Denver
Florida, Fort Lauderdale
Florida, Sanford
Iowa, Davenport
Missouri, Columbia
New Jersey, Somerset
New York, Albany
Oregon, Portland
Tennessee, Gray
West Virginia, Morgantown
Wisconsin, Milwaukee



PYLARIFY® Piflufolastat F 18 Injection

PYLARIFY availability is expected to continually expand across the U.S.

Piflufolastat F 18 Added to NCCN Guidelines and SNMMI Appropriate Use Criteria

RADIOPHARMACEUTICAL ONCOLOGY

Piflufolastat F 18 now included in the guidelines in the areas of unfavorable intermediate, high and very high risk, as well as recurrent disease for the management of prostate cancer

NCCN National Comprehensive Cancer Network®

ACNM American College of Nuclear Medicine

ASCO American Society of Clinical Oncology

American Urological Association

ACP American College of Physicians® Leading Internal Medicine, Improving Lives

SNMMI Value Initiative

Society of Nuclear Medicine & Molecular Imaging

Further facilitates the commercial adoption of PYLARIFY as it raises awareness in the medical and payer communities

PYLARIFY: Progressed Market Access Initiatives and Completed Commercial Infrastructure Build-Out

RADIOPHARMACEUTICAL ONCOLOGY

PYLARIFY®
Piflufolastat F 18 Injection

MARKET ACCESS

- Pass-through application submitted to the Centers for Medicare & Medicaid Services (CMS)
  - Expect pass-through payment to go into effect January 1, 2022
- HCPCS code will become effective January 1, 2022
- Majority of Medicare Administrative Contactors have paid claims, published guidance or indicated they will cover PYLARIFY
- Prior authorizations are being approved and claims paid by both Medicare Advantage and commercial insurers
- Continue to work with payers to have formal policies updated in 2022

FIELD TEAM BUILD-OUT

Completed the build-out of our fully dedicated PSMA PET sales force and market access teams

We continue to expand our geographic coverage, customer adoption and market access coverage to serve our customers and the U.S. Prostate Cancer community

PYLARIFY AI: Improves Consistency and Productivity of PSMA Imaging

FIRST AND ONLY FDA CLEARED*
Artificial Intelligence-Enabled PSMA Digital Application



Artificial intelligence medical device software to assist with interpreting PYLARIFY scans

Uses a deep learning algorithm, trained and validated using more than 3,000 PSMA images

*Cleared under the name aPROMISE and will be launched under the name PYLARIFY AI

PYLARIFY AI™

Standardized platform for physicians and researchers to **efficiently, consistently and accurately** quantify PSMA uptake at the lesion level for men with prostate cancer

Introduced the application to researchers and key opinion leaders at the 28th Annual Prostate Cancer Foundation Scientific Retreat

Launching at the Radiological Society of North America (RSNA) meeting

Five leading cancer centers are already in the process of adding PYLARIFY AI digital application into their prostate cancer diagnostic workflows

RADIOPHARMACEUTICAL ONCOLOGY

AZEDRA®

iobenguane I 131 injection for intravenous use

Lantheus Holdings

AZEDRA: Treating Patients with Pheochromocytoma and Paraganglioma (PPGL)

Rare cancers with high unmet need

~650 – 2,600 patients diagnosed each year in US[1,2]

15% of cases are advanced at diagnosis[1]

Disease recurs in 16.4% of patients treated surgically[3]

Tumor progression is the most frequent cause of death

The 5-year overall survival of patients with advanced PPGL varies, but can be as low as 12%[4]

(1) Martucci VL, Pacak K. Curr Probl Cancer. 2014;38(1):7-41.
(2) US Census Bureau. US and World Population Clock. https://www.census.gov/popclock/. Accessed October 1, 2017.
(3) Kantorovich V, Eisenhofer G, Pacak K. Ann N Y Acad Sci. 2009;1148:462-468.
(4) Long-Term Survival and Safety from a Multi-Center, Open-Label Pivotal Phase 2 Study of AZEDRA IN Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma ASCO Abstract 2019, Noto et al.

AZEDRA® iobenguane I 131 injection for intravenous use

First and Only FDA Approved Treatment for Patients with PPGL

COMMERCIAL AND MEDICAL AFFAIRS

- Our Commercial team has been working with academic centers of excellence in key markets across the U.S. in preparation for future demand
- We have continued to build out the Medical Affairs team that will interface with stakeholders

MANUFACTURING

- Increased the manufacturing staff at our Somerset facility to ensure ongoing adequate product supply
- Constructing an additional manufacturing suite* to provide redundancy for AZEDRA manufacturing, as well as increased overall future capacity of our iodine-based products.

We remain committed to providing patients with locally advanced or metastatic pheochromocytoma and paraganglioma with access to AZEDRA

* Subject to FDA approval

Pharma Services & Other Partnerships

Lantheus Holdings

Pharma Services: Enabling Precision Medicine with Biomarkers and Digital Solutions that Augment Diagnostic Productivity

Prostate

piflufolastat F 18

aBSI AUTOMATED BONE SCAN INDEX aPROMISE

- Precision biomarkers offered to pharmaceutical companies developing therapies in prostate cancer
  - Clinical supply agreements with Regeneron, Bayer and POINT BioPharma for use of piflufolastat F 18 in prostate cancer drug development programs
  - Development and commercialization collaboration with RefleXion Medical, Inc. to evaluate the use of piflufolastat F 18 with biology-guided radiotherapy in prostate cancer

Immuno-Oncology

NM-01 – PDL1

- Acquired rights to NM-01 from NanoMab, a PD-L1 imaging biomarker product candidate
  - For potential use by pharmaceutical companies and academic centers conducting clinical trials of immuno-oncology therapies, including combination therapies

Pan-Oncology

NTI-1309 – FAP

- Acquired rights to NTI-1309, an innovative imaging biomarker that targets fibroblast activation protein (FAP), from Ratio Therapeutics (formerly Noria Therapeutics)
  - FAP is an emerging target with broad potential applicability in oncology
  - We are integrating NTI-1309 into our portfolio of imaging biomarkers as part of our Pharma Services offering. Upon further clinical development, we will assess options to bring NTI-1309 to market as a diagnostic or potentially a therapeutic agent.

CURRENT PARTNERS

BAYER POINT BIOPHARMA REGENERON reflexion Ratio Therapeutics NANOMAB

Pipeline



Lantheus Holdings

Robust Pipeline with Promising Value Drivers



(1) Using Lantheus microbubble.

1095 Phase 2 Trial Ongoing - Interim Analysis Completed

Independent Data Monitoring Committee recommended the study continue without modifications

PSMA-targeted iodine-131 labeled small molecule therapeutic that is designed to deliver beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues

ARROW
Phase 2 Study

25 clinical sites in the U.S. and Canada support enrollment for our multicenter, randomized, controlled study for men with metastatic castration-resistant prostate cancer (mCRPC)



Financials

Lantheus Holdings

Strong Balance Sheet and Financial Flexibility Sets Foundation for Growth

Decline in Debt



Strong Balance Sheet
(Q3 2021)

1.95x
NET LEVERAGE*

	Three Months Ending September 30,	
$M	2021[1]	2020[1]
Cash From Operations	$4.3	$8.6
Cash Used in Investing	($2.4)	($3.7)
Cash Used In Financing	($1.7)	($7.3)

(1) Free Cash Flow was $1.9M and $4.8M for the three months ended September 30, 2021 and 2020, respectively.

Resources
(Q3 2021)

Cash on hand[1] **$91.5M**

Available revolving credit **$200M**

(1) Cash, cash equivalents and restricted cash at the end of the period was $93.6M.

* The net leverage ratio presented relates directly to the Company's June 2019 Credit Facility covenant calculation.

Q3 2021 and Updated FY 2021 Financial Guidance[1]

Guidance Issued November 4, 2021

The Company guidance for the fourth quarter and updated for the full year 2021 is as follows:

Q4 FY 2021	**Revenue[2]**	$110 million - $115 million
	Adjusted Fully Diluted EPS[2,3]	$0.15 - $0.18

FY 2021	Prior Revenue[2]	$395 million - $402 million
	Current Revenue[2]	**$405 million - $410 million**
	Prior Adjusted Fully Diluted EPS[2,3]	$0.38 - $0.42
	Current Adjusted Fully Diluted EPS[2,3]	**$0.40 - $0.43**

(1) On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments (including liability accruals relating to the contingent value rights issued as part of the Progenics Pharmaceuticals, Inc. acquisition), and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company's view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.

(2) Represents approximate summation of three quarters of actuals plus fourth quarter's forecast; Sale of Lantheus' Puerto Rico radiopharmacy and PET manufacturing facility closed on January 29, 2021. During 2020, the Puerto Rico business generated $10.7M of Net Revenue and $1.8M of Adjusted Net Income; FY 2021 guidance excludes contribution from the Puerto Rico, assumption of broad COVID-19 vaccination distribution and approval of PYLARIFY on May 26, 2021.

(3) FY 2021 guidance assumes fully diluted, weighted avg. shares outstanding of 68M-69M, and depreciation and amortization of ~$15M and ~$25M, respectively.

In Summary

DEFINITY

- DEFINITY delivered a solid quarter and maintains market leadership; significant long-term growth potential
- Filed sNDA for on-campus manufacturing facility to supplement DEFINITY supply

PYLARIFY

- Robust adoption during first full quarter since approval and significant momentum heading into the fourth quarter and 2022
- PMF footprint expanded to serve ~70% of the U.S. population
- Received FDA clearance for PYLARIFY AI and launching later this month

FINANCIALS

- Three largest products – DEFINITY, TechneLite and PYLARIFY – posted growth during the quarter, even as certain aspects of the business were impacted by the resurgence of COVID-19
- Strong adjusted earnings with continued financial strength informing updated full year guidance

Committed to building on positive momentum and delivering shareholder value

Appendix

Piflufolastat F 18: Progressing Use as a Biomarker in Prostate Cancer Therapeutic Trials

Ongoing Clinical Trials

POINT BIOPHARMA	Phase 3 Pivotal Trial	• Lutetium-labeled PSMA agent in patients with mCRPC
REGENERON	Phase 1 Trial	• PSMAxCD28 bispecific antibody in combination with cemiplimab (PD-1 inhibitor) in patients with mCRPC
	Phase 1/2 Trial	• PSMAxCD3 bispecific antibody in combination with cemiplimab in patients with mCRPC
BAYER	Phase 1 Trial	• Thorium-labeled PSMA antibody in patients with mCRPC
Lantheus FIND > FIGHT > FOLLOW™	Phase 2 Trial	• Iodine-labeled PSMA agent (1095) in patients with mCRPC

Piflufolastat F 18 used to assess PSMA expression levels in clinical trials for prostate cancer therapeutics

Strategic Partnerships Across Our Portfolio

Oncology

piflufolastat F 18

REGENERON

BAYER

POINT BIOPHARMA

CURIUM™

reflexion

1404

ROTOP

PSMA TTC

BAYER

aBSI

GE Healthcare

Biomarker

RATIO THERAPEUTICS, INC.

NANOMAB

Microbubble

CEREVAST™

INSIGHTEC®

CARTHERA Advanced Brain Therapy Through Innovation

AHN

RELISTOR

BAUSCH+ Health

flurpiridaz F18

GE Healthcare

U.S. Approved Products

AZEDRA® iobenguane I 131 injection for intravenous use

aBSI AUTOMATED BONE SCAN INDEX

Cardiolite® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection

DEFINITY® VIAL FOR (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION

DEFINITY RT (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION

Gallium Gallium Citrate Ga 67 Injection

NEUROLITE® Kit for the Preparation of Technetium Tc 99m Bicisate for Injection

PYLARIFY® Piflufolastat F 18 Injection

PYLARIFY AI™ *

QUADRAMET® ** (SAMARIUM SM 153 LEXIDRONAM INJECTION)

RELISTOR® methylnaltrexone bromide

TechneLite® Technetium Tc 99m Generator

Thallium Thallous Chloride Tl 201 Injection

Xenon Xe 133 Gas

* Granted 510(k) clearance by the U.S. FDA. ** Product no longer available for commercial sale

Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share data – unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Net loss	$ (13,415)	$ (6,386)	$ (31,064)	$ (10,061)
Stock and incentive plan compensation	3,867	3,992	11,772	10,452
Amortization of acquired intangible assets	8,374	4,768	19,133	6,087
Acquired debt fair value adjustment	—	(385)	(307)	(385)
Contingent consideration fair value adjustments	2,600	800	28,500	800
Non-recurring refinancing related fees	—	—	—	460
Non-recurring severance related fees	(6)	—	522	—
Extinguishment of debt	—	—	(889)	—
Gain on sale of assets	—	—	(15,263)	—
Integration costs	63	855	93	4,428
Acquisition-related costs	62	1,593	726	10,522
Impairment of long-lived assets	9,540	—	9,540	7,275
Other	7	—	60	(75)
Income tax effect of non-GAAP adjustments[(a)]	(5,411)	(2,819)	(6,059)	(8,265)
Adjusted net income	$ 5,681	$ 2,418	$ 16,764	$ 21,238
Adjusted net income, as a percentage of revenues	5.6 %	2.7 %	5.7 %	8.7 %
Adjusted EBITDA	$ 15,959	$ 13,223	$ 48,247	$ 55,059

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Net loss per share - diluted	$ (0.20)	$ (0.10)	$ (0.46)	$ (0.20)
Stock and incentive plan compensation	0.05	0.06	0.18	0.21
Amortization of acquired intangible assets	0.12	0.08	0.28	0.12
Acquired debt fair value adjustment	—	(0.01)	(0.01)	(0.01)
Contingent consideration fair value adjustments	0.04	0.01	0.42	0.01
Non-recurring refinancing related fees	—	—	—	0.01
Non-recurring severance related fees	—	—	0.01	—
Extinguishment of debt	—	—	(0.01)	—
Gain on sale of assets	—	—	(0.23)	—
Integration costs	—	0.01	—	0.09
Acquisition-related costs	0.01	0.02	0.01	0.21
Impairment of long-lived assets	0.14	—	0.14	0.14
Other	—	—	—	—
Income tax effect of non-GAAP adjustments[(a)]	(0.08)	(0.03)	(0.09)	(0.16)
Adjusted net income per share - diluted	$ 0.08	$ 0.04	$ 0.24	$ 0.42
Weighted-average common shares outstanding - diluted	69,237	67,006	68,674	50,210

(a) The income tax effect of the adjustments between GAAP net loss and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

Reconciliation of Free Cash Flow
(in thousands – unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Net cash provided by operating activities	$ 4,340	$ 8,575	$ 40,027	$ 15,827
Capital expenditures	(2,420)	(3,736)	(7,596)	(8,689)
Free cash flow	$ 1,920	$ 4,839	$ 32,431	$ 7,138
Net cash (used in) provided by investing activities	$ (2,420)	$ (3,736)	$ 8,227	$ (1,127)
Net cash used in financing activities	$ (1,726)	$ (7,270)	$ (37,232)	$ (17,488)

PYLARIFY: Strong Diagnostic Performance Across the Prostate Cancer Disease Continuum

CONDOR Study

Diagnostic Performance of ^{18}F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study

OSPREY Study

A Phase 2/3 Prospective Multicenter Study of Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with ^{18}F-DCFPyL in Prostate Cancer Patients (OSPREY)

PYLARIFY Pivotal Studies

CONDOR

OSPREY

~600 subjects

PYLARIFY NDA

Two pivotal trials supported the approval of the NDA which was granted Priority Review

Lantheus Holdings



Credit Suisse 30th Annual Healthcare Conference Presentation

November 11, 2021

FIND > FIGHT > FOLLOW™